MX363817B - Métodos para predecir el desenlace clínico del cáncer. - Google Patents
Métodos para predecir el desenlace clínico del cáncer.Info
- Publication number
- MX363817B MX363817B MX2016003089A MX2016003089A MX363817B MX 363817 B MX363817 B MX 363817B MX 2016003089 A MX2016003089 A MX 2016003089A MX 2016003089 A MX2016003089 A MX 2016003089A MX 363817 B MX363817 B MX 363817B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- methods
- genes
- clinical outcome
- prognosis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000004393 prognosis Methods 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 238000007405 data analysis Methods 0.000 abstract 1
- 238000007619 statistical method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26376309P | 2009-11-23 | 2009-11-23 | |
| PCT/US2010/057490 WO2011063274A2 (en) | 2009-11-23 | 2010-11-19 | Methods to predict clinical outcome of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX363817B true MX363817B (es) | 2019-04-04 |
Family
ID=44060376
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003089A MX363817B (es) | 2009-11-23 | 2010-11-19 | Métodos para predecir el desenlace clínico del cáncer. |
| MX2012005822A MX337650B (es) | 2009-11-23 | 2010-11-19 | Metodos para predecir el desenlace clinico del cancer. |
| MX2019003811A MX391499B (es) | 2009-11-23 | 2010-11-19 | Metodos para predecir el desenlace clinico del cancer. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012005822A MX337650B (es) | 2009-11-23 | 2010-11-19 | Metodos para predecir el desenlace clinico del cancer. |
| MX2019003811A MX391499B (es) | 2009-11-23 | 2010-11-19 | Metodos para predecir el desenlace clinico del cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20110123990A1 (enExample) |
| EP (4) | EP3556867A1 (enExample) |
| JP (7) | JP5964752B2 (enExample) |
| AU (1) | AU2010321829B2 (enExample) |
| CA (2) | CA3043089A1 (enExample) |
| DK (1) | DK2504451T3 (enExample) |
| ES (1) | ES2735993T3 (enExample) |
| HU (1) | HUE044374T2 (enExample) |
| IL (5) | IL219051A (enExample) |
| MX (3) | MX363817B (enExample) |
| NZ (1) | NZ599194A (enExample) |
| PL (1) | PL2504451T3 (enExample) |
| WO (1) | WO2011063274A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| EP1737980A2 (en) | 2004-04-09 | 2007-01-03 | Fondazione IRCCS Istituto Nazionale dei Tumori | Gene expression markers for predicting response to chemotherapy |
| CA2585571C (en) * | 2004-11-05 | 2020-01-21 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
| US7888019B2 (en) | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
| MX2010014280A (es) * | 2008-06-26 | 2011-05-23 | Dana Farber Cancer Inst Inc | Distintivos y determinantes asociados con metástasis y método para utilizarlos. |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| JP5964752B2 (ja) * | 2009-11-23 | 2016-08-03 | ジェノミック ヘルス， インコーポレイテッド | 癌の臨床転帰を予測する方法 |
| MX375138B (es) | 2010-01-11 | 2025-03-06 | Genomic Health Inc | Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal. |
| GB201009798D0 (en) | 2010-06-11 | 2010-07-21 | Immunovia Ab | Method,array and use thereof |
| US20120053253A1 (en) | 2010-07-07 | 2012-03-01 | Myriad Genetics, Incorporated | Gene signatures for cancer prognosis |
| EP2913405B1 (en) | 2010-07-27 | 2016-11-09 | Genomic Health, Inc. | Method for using gene expression to determine prognosis of prostate cancer |
| EP2611941A4 (en) | 2010-08-30 | 2014-01-22 | Myriad Genetics Inc | GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS |
| US8361720B2 (en) | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| US8916344B2 (en) | 2010-11-15 | 2014-12-23 | Exact Sciences Corporation | Methylation assay |
| CA2831074A1 (en) * | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Gene expression predictors of cancer prognosis |
| CA2840472A1 (en) * | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
| WO2013006495A2 (en) * | 2011-07-01 | 2013-01-10 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
| AU2012281152B2 (en) * | 2011-07-13 | 2017-09-07 | The Multiple Myeloma Research Foundation, Inc. | Methods for data collection and distribution |
| EP2744917A4 (en) * | 2011-08-16 | 2015-10-14 | Oncocyte Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER |
| WO2013070521A1 (en) * | 2011-11-08 | 2013-05-16 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
| JP5805518B2 (ja) * | 2011-12-21 | 2015-11-04 | 株式会社島津製作所 | マルチプレックス大腸がんマーカーパネル |
| US8725426B2 (en) | 2012-01-31 | 2014-05-13 | Genomic Health, Inc. | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| GB201206323D0 (en) * | 2012-04-10 | 2012-05-23 | Immunovia Ab | Methods and arrays for use in the same |
| EP2839034A4 (en) * | 2012-04-20 | 2016-01-06 | Sloan Kettering Inst Cancer | ASSOCIATED GENE EXPRESSION PROFILES ASSOCIATED WITH METASTASISING BREAST CANCER |
| WO2014055398A1 (en) | 2012-10-05 | 2014-04-10 | Siemens Healthcare Diagnostics Inc. | Method for detecting an increased risk or incidence of colorectal cancer |
| ES2938766T3 (es) | 2012-11-16 | 2023-04-14 | Myriad Genetics Inc | Firmas génicas para el pronóstico de cáncer |
| KR101672531B1 (ko) * | 2013-04-18 | 2016-11-17 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도 |
| US10181008B2 (en) * | 2013-05-30 | 2019-01-15 | Genomic Health, Inc. | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
| WO2014195032A1 (en) * | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| WO2015138769A1 (en) * | 2014-03-12 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for assessing patients with non-small cell lung cancer |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| US10570457B2 (en) | 2014-09-26 | 2020-02-25 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| WO2016092299A1 (en) * | 2014-12-09 | 2016-06-16 | Medical Research Council | Methods and kits for predicting the response to therapy of cancer |
| EP3274440B1 (en) | 2015-03-27 | 2026-03-04 | Exact Sciences Corporation | Detecting esophageal disorders |
| KR102811214B1 (ko) | 2015-10-30 | 2025-05-27 | 이그잭트 사이언시즈 코포레이션 | 복합 증폭 검출 분석 및 혈장으로부터 dna의 분리 및 검출 방법 |
| EP3389481A4 (en) | 2015-12-18 | 2019-05-22 | Clear Gene, Inc. | PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS |
| SG11201901466PA (en) * | 2016-09-07 | 2019-03-28 | Agency Science Tech & Res | A method of identifying risk of cancer and therapeutic options |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| JP7289264B2 (ja) | 2017-01-27 | 2023-06-09 | エグザクト サイエンシーズ コーポレーション | メチル化ｄｎａの分析による結腸腫瘍の検出 |
| WO2018212192A1 (ja) * | 2017-05-18 | 2018-11-22 | 京都府公立大学法人 | 癌の予後及び／又は転移可能性を評価する方法及びマーカー |
| US12275994B2 (en) * | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| CA3036161C (en) | 2017-11-13 | 2023-03-28 | The Multiple Myeloma Research Foundation, Inc. | Integrated, molecular, omics, immunotherapy, metabolic, epigenetic, and clinical database |
| US10648025B2 (en) | 2017-12-13 | 2020-05-12 | Exact Sciences Development Company, Llc | Multiplex amplification detection assay II |
| US11549152B2 (en) * | 2018-03-08 | 2023-01-10 | University Of Notre Dame Du Lac | Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon |
| JP7199045B2 (ja) * | 2018-04-13 | 2023-01-05 | 国立大学法人大阪大学 | 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム |
| US20220120753A1 (en) * | 2018-09-21 | 2022-04-21 | The University Of Tokyo | Method for determining prognosis of cancer |
| JP2019032334A (ja) * | 2018-10-03 | 2019-02-28 | イムノヴィア・アクチエボラーグ | 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ |
| KR102216645B1 (ko) * | 2018-10-29 | 2021-02-17 | 사회복지법인 삼성생명공익재단 | 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도 |
| MX2021006560A (es) * | 2018-12-08 | 2021-11-17 | Pfs Genomics Inc | Perfilado transcriptómico para prognosis de cáncer de mama. |
| SG11202111940XA (en) * | 2019-05-03 | 2021-12-30 | Dcgen Co Ltd | Method of predicting cancer prognosis and composition for same |
| CN111235270B (zh) * | 2019-08-29 | 2022-04-29 | 北京臻知医学科技有限责任公司 | 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒 |
| US12165747B2 (en) * | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| AU2022220330A1 (en) * | 2021-02-12 | 2023-09-14 | Mammogen, Inc. | Biomarkers for the diagnosis of breast cancer |
| WO2022192128A2 (en) * | 2021-03-08 | 2022-09-15 | Castle Biosciences, Inc. | Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores |
| CN117116345B (zh) * | 2023-07-24 | 2025-09-16 | 中国人民解放军军事科学院军事医学研究院 | 一种基于基因调控网络构建患者生存网络的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1410011T3 (da) | 2001-06-18 | 2011-07-18 | Netherlands Cancer Inst | Diagnose og prognose for brystcancerpatienter |
| US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| AU2002322280A1 (en) * | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| DK3115470T3 (en) * | 2002-03-13 | 2018-11-05 | Genomic Health Inc | Gene Expression Profiling in Tumor Tissue Biopsies |
| US20040067234A1 (en) * | 2002-07-11 | 2004-04-08 | Paz Einat | Isocitrate dehydrogenase and uses thereof |
| US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| ES2905579T3 (es) * | 2003-07-10 | 2022-04-11 | Genomic Health Inc | Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama |
| WO2005086891A2 (en) * | 2004-03-05 | 2005-09-22 | Rosetta Inpharmatics Llc | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
| CA2582739A1 (en) * | 2004-09-30 | 2006-04-13 | Bayer Healthcare Ag | Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy |
| JP2008534002A (ja) | 2005-04-01 | 2008-08-28 | エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド | 乳癌の分類に関する材料および方法 |
| WO2006133460A2 (en) | 2005-06-09 | 2006-12-14 | Yale University | Methods for diagnosing and treating breast cancer based on a her/er ratio |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2006138275A2 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| TWI304443B (en) * | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| US7888019B2 (en) * | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
| US20100234292A1 (en) * | 2007-04-16 | 2010-09-16 | Ipsogen | Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer |
| WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
| WO2009095319A1 (en) * | 2008-01-28 | 2009-08-06 | Siemens Healthcare Diagnostics Gmbh | Cancer prognosis by majority voting |
| WO2009132928A2 (en) * | 2008-05-02 | 2009-11-05 | Siemens Healthcare Diagnostics Gmbh | Molecular markers for cancer prognosis |
| CA2723972A1 (en) * | 2008-05-12 | 2009-11-19 | Genomic Health Inc. | Tests to predict responsiveness of cancer patients to chemotherapy treatment options |
| JP5964752B2 (ja) * | 2009-11-23 | 2016-08-03 | ジェノミック ヘルス， インコーポレイテッド | 癌の臨床転帰を予測する方法 |
-
2010
- 2010-11-19 JP JP2012540103A patent/JP5964752B2/ja active Active
- 2010-11-19 EP EP19175741.8A patent/EP3556867A1/en not_active Withdrawn
- 2010-11-19 MX MX2016003089A patent/MX363817B/es unknown
- 2010-11-19 HU HUE10832289 patent/HUE044374T2/hu unknown
- 2010-11-19 DK DK10832289.2T patent/DK2504451T3/da active
- 2010-11-19 CA CA3043089A patent/CA3043089A1/en not_active Withdrawn
- 2010-11-19 EP EP23213439.5A patent/EP4350001A3/en active Pending
- 2010-11-19 PL PL10832289T patent/PL2504451T3/pl unknown
- 2010-11-19 US US12/950,732 patent/US20110123990A1/en not_active Abandoned
- 2010-11-19 CA CA2776751A patent/CA2776751C/en active Active
- 2010-11-19 EP EP10832289.2A patent/EP2504451B1/en active Active
- 2010-11-19 ES ES10832289T patent/ES2735993T3/es active Active
- 2010-11-19 NZ NZ599194A patent/NZ599194A/en unknown
- 2010-11-19 AU AU2010321829A patent/AU2010321829B2/en active Active
- 2010-11-19 MX MX2012005822A patent/MX337650B/es active IP Right Grant
- 2010-11-19 WO PCT/US2010/057490 patent/WO2011063274A2/en not_active Ceased
- 2010-11-19 EP EP20177718.2A patent/EP3739060A1/en not_active Withdrawn
- 2010-11-19 MX MX2019003811A patent/MX391499B/es unknown
-
2012
- 2012-04-04 IL IL219051A patent/IL219051A/en active IP Right Grant
-
2016
- 2016-06-30 JP JP2016129697A patent/JP2016214245A/ja active Pending
- 2016-11-23 IL IL249159A patent/IL249159A0/en unknown
-
2017
- 2017-02-03 US US15/423,977 patent/US20170211154A1/en not_active Abandoned
-
2018
- 2018-01-21 IL IL257063A patent/IL257063B/en active IP Right Grant
- 2018-08-02 JP JP2018145578A patent/JP7042717B2/ja active Active
-
2019
- 2019-01-03 IL IL264072A patent/IL264072B/en active IP Right Grant
- 2019-01-09 US US16/243,207 patent/US20190241967A1/en not_active Abandoned
-
2020
- 2020-08-04 IL IL276487A patent/IL276487B/en unknown
- 2020-09-11 US US17/018,143 patent/US20210062275A1/en not_active Abandoned
- 2020-12-28 JP JP2020218527A patent/JP2021058207A/ja active Pending
-
2022
- 2022-08-02 JP JP2022123265A patent/JP2022166064A/ja active Pending
- 2022-08-16 JP JP2022129605A patent/JP2022169647A/ja active Pending
-
2023
- 2023-12-18 JP JP2023213416A patent/JP7823012B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX363817B (es) | Métodos para predecir el desenlace clínico del cáncer. | |
| Pallis et al. | Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? | |
| Wang et al. | Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis | |
| WO2005086891A3 (en) | Classification of breast cancer patients using a combination of clinical criteria and informative genesets | |
| MX346031B (es) | Método para emplear expresión génica para determinar pronóstico de cáncer de próstata. | |
| NZ593225A (en) | Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis | |
| ES2938766T3 (es) | Firmas génicas para el pronóstico de cáncer | |
| IN2012DN04944A (enExample) | ||
| MX337333B (es) | Metodos y sistemas para evaluar resultados clinicos. | |
| MX2013000502A (es) | Metodos y kits para el diagnostico de cancer de prostata. | |
| MX351626B (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| Deshpande et al. | Development of a claims-based algorithm to identify colorectal cancer recurrence | |
| Pavlík et al. | Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000–2008 | |
| Lund et al. | Development and validation of a 5‐year mortality prediction model using regularized regression and Medicare data | |
| Alam et al. | Prostate cancer genomics: Comparing results from three molecular assays | |
| Ku et al. | Risk prediction models of locoregional failure after radical cystectomy for urothelial carcinoma: external validation in a cohort of korean patients | |
| Da et al. | Upregulation of the long non-coding RNA FAM83H-AS1 in gastric cancer and its clinical significance | |
| Mello et al. | Machine learning supports long noncoding rnas as expression markers for endometrial carcinoma | |
| Kim et al. | Clinical implications and prognostic values of prostate cancer susceptibility candidate methylation in primary nonmuscle invasive bladder cancer | |
| Jahreiβ et al. | Long-term Overall Survival after External Beam Radiotherapy for Localised Prostate Cancer | |
| WO2010091296A3 (en) | Emx2 in cancer diagnosis and prognosis | |
| WO2006065940A3 (en) | Identification and use of prognostic and predictive markers in cancer treatment | |
| Tang et al. | Pan‐cancer analysis reveals molecular signatures for predicting matrix stiffness in solid tumors | |
| Samuels et al. | The cancer genome |